Literature DB >> 20721788

Retrospective robustness of the continual reassessment method.

John O'Quigley1, Sarah Zohar.   

Abstract

We study model sensitivity of the continual reassessment method (CRM). The context is that of dose-finding designs where certain design parameters are fixed by the investigator. Although our focus is on the CRM (O'Quigley et al., 1990), the essential ideas can be applied to any sequential dose-finding method. It is expected that different choices of a model family and particular parameterizations will have an impact on performance. Assuming that the constraints outlined in Shen and O'Quigley (1996) are respected, large sample performance is unaffected. However small sample performance will be affected by these choices, which are to some degree arbitrary. This work focuses on the retrospective robustness of the CRM in practice. The question is not of a general theoretical nature where, in the background, we would want to consider large numbers of true potential situations. Instead, the question is raised in the specific context of any actual completed study and is the following: Would we have come to the same conclusion concerning the MTD had we worked with a design specified differently? The sequential nature of the CRM means that this question cannot be answered in any definitive way. We can, though, by appealing to the retrospective CRM (O'Quigley, 2005), provide consistent estimates of the relationships between the MTD and the chosen model. If these estimates suggest that changes in different family model parameters will be accompanied by changes in final recommendation, then we would not be confident in the reliability of the estimated MTD and more work would be needed. Also, of course, at the planning stage, prospective robustness could be studied by simulating trials using particular models and parameterizations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20721788     DOI: 10.1080/10543400903315732

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  14 in total

1.  A Phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanoma.

Authors:  Nolan A Wages; Craig L Slingluff; Gina R Petroni
Journal:  Contemp Clin Trials       Date:  2015-01-29       Impact factor: 2.226

2.  A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies.

Authors:  Akihiro Hirakawa; Nolan A Wages; Hiroyuki Sato; Shigeyuki Matsui
Journal:  Stat Med       Date:  2015-05-13       Impact factor: 2.373

Review 3.  Extended model-based designs for more complex dose-finding studies.

Authors:  John O'Quigley; Mark Conaway
Journal:  Stat Med       Date:  2011-02-24       Impact factor: 2.373

Review 4.  Practical designs for Phase I combination studies in oncology.

Authors:  Nolan A Wages; Anastasia Ivanova; Olga Marchenko
Journal:  J Biopharm Stat       Date:  2016       Impact factor: 1.051

5.  Seamless Phase I/II Adaptive Design for Oncology Trials of Molecularly Targeted Agents.

Authors:  Nolan A Wages; Christopher Tait
Journal:  J Biopharm Stat       Date:  2014-06-06       Impact factor: 1.051

6.  A Phase I/II adaptive design for heterogeneous groups with application to a stereotactic body radiation therapy trial.

Authors:  Nolan A Wages; Paul W Read; Gina R Petroni
Journal:  Pharm Stat       Date:  2015-05-11       Impact factor: 1.894

7.  Interplay of priors and skeletons in two-stage continual reassessment method.

Authors:  Alexia Iasonos; John O'Quigley
Journal:  Stat Med       Date:  2012-08-15       Impact factor: 2.373

8.  pocrm: an R-package for phase I trials of combinations of agents.

Authors:  Nolan A Wages; Nikole Varhegyi
Journal:  Comput Methods Programs Biomed       Date:  2013-07-18       Impact factor: 5.428

9.  Phase I/II adaptive design for drug combination oncology trials.

Authors:  Nolan A Wages; Mark R Conaway
Journal:  Stat Med       Date:  2014-01-28       Impact factor: 2.373

10.  Specifications of a continual reassessment method design for phase I trials of combined drugs.

Authors:  Nolan A Wages; Mark R Conaway
Journal:  Pharm Stat       Date:  2013-06-03       Impact factor: 1.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.